{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}],"title":"MMR (Overall)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"title":"CMR (Unconfirmed)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"CMR (Confirmed)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Molecular response was calculated by measuring p210 variant of BCR-ABL transcripts in blood during treatment using quantitative polymerase chain reaction (qPCR) assay. Major molecular response (MMR): Ratio of the BCR-ABL to ABL \\<10\\^-3 or 0.1% on the international scale. Complete molecular response (CMR): Complete absence of BCR-ABL or the ratio is \\<10\\^-4.5 or 0.00316% on the international scale. Confirmed MMR or CMR = Criteria met again \\>6 weeks. BCR-ABL=the fused gene found in participants with this type of CML.","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants in stratum 1: Participants who received at least 1 dose of study therapy.","reportingStatus":"POSTED","timeFrame":"At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])","title":"Number of Participants With Molecular Responses in Stratum 1 (Ph+ CP-CML)","type":"SECONDARY","unitOfMeasure":"participants"}